Finerenone-potential-reduce-onset-atrial-fibrillation-flutter-patients-chronic-kidney-disease-2

A prespecified exploratory analysis of the FIDELIO-DKD study demonstrates that finerenone may significantly reduce the risk of new onset atrial fibrillation or flutter (AFF) in patients with CKD and T2D versus placebo when added to standard of care / This analysis also concluded that finerenone reduced the risk of kidney or cardiovascular events with no significant difference in the effect of finerenone between patients with and without history of AFF at baseline / Based on the comprehensive finerenone clinical trial program, finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate cardiovascular and renal benefits in patients with chronic kidney disease and type 2 diabetes / Results from the exploratory analysis were simultaneously published in the Journal of the American College of Cardiology
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news